Aytu BioScience, Inc. AYTU 深 滬
等待開盤 12-17 09:30:00 美东时间
2.42
+0.090
+3.86%
華盛通- 最 高2.4734
- 今 開2.36
- 成交量 15.28万股
- 最 低 2.32
- 昨 收 2.33
- 總市值 2398.68万
- 52周最高 2.82
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.95
- 委 比 75.00%
- 總股本 991.19万
- 歷史最高 12920.00
- 量 比 1.88
- 振 幅 6.58%
- 歷史最低 0.95
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $12.5 to $13.
12-10 18:31
Aytu BioPharma Q1 Adj. EPS $(0.08) Beats $(0.23) Estimate, Sales $13.900M Beat $12.397M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.23) by 65.22 percent. This is a 60 percent increase over losses of $(0.20) per share from the
11-14 05:09
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Aytu BioPharma Secures Patent Extension For EXXUA Through 2030, Expanding FDA NCE Exclusivity Period
Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,
10-28 21:03
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and raises the price target from $12 to $12.5.
09-25 20:04
Aytu BioPharma’s Optimistic Earnings Call Highlights ExuA Launch
Aytu BioScience (($AYTU)) has held its Q4 earnings call. Read on for the main h...
09-25 08:02
Aytu BioPharma推出指向价值220亿美元重度抑郁症市场的计划
Aytu BioPharma（AYTU）概述了推出EXXUA的计划，目标是价值220亿美元的重度抑郁症市场。公司正将重心转向处方药，EXXUA提供了一种新的...
09-24 23:23
Aytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolio
Earnings Call Insights: Aytu BioPharma (AYTU) Q4 2025 Management View CEO Joshua Disbrow highlighted "the strong financial performance during the recent fiscal year and perhaps more importantly, the u...
09-24 09:44
